Article Text

Download PDFPDF

Original article
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
  1. Nicola A Hanania1,
  2. Michael Noonan2,
  3. Jonathan Corren3,
  4. Phillip Korenblat4,
  5. Yanan Zheng5,
  6. Saloumeh K Fischer5,
  7. Melissa Cheu5,
  8. Wendy S Putnam5,
  9. Elaine Murray5,
  10. Heleen Scheerens5,
  11. Cecile TJ Holweg5,
  12. Romeo Maciuca5,
  13. Sarah Gray5,
  14. Ramona Doyle5,
  15. Dana McClintock5,
  16. Julie Olsson5,
  17. John G Matthews5,
  18. Karl Yen5
  1. 1Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USA
  2. 2Allergy Associates Research, Portland, Oregon, USA
  3. 3Asthma and Allergy Research Foundation, Los Angeles, California, USA
  4. 4Clinical Research Center LLC, St. Louis, Missouri, USA
  5. 5Genentech Inc. (a Member of the Roche Group), South San Francisco, California, USA
  1. Correspondence to Dr Karl Yen, Genentech Inc, 1 DNA Drive, South San Francisco, CA 94080-4990, USA; yen.karl{at}


Introduction In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a humanised, monoclonal antibody that binds to and blocks interleukin-13 activity.

Methods LUTE and VERSE were replicate, randomised, double-blind, placebo-controlled studies, evaluating multiple doses of lebrikizumab in patients with uncontrolled asthma despite the use of medium-to-high-dose inhaled corticosteroid and a second controller. Patients received lebrikizumab 37.5, 125, 250 mg or placebo subcutaneously every four weeks. The primary endpoint was the rate of asthma exacerbations during the placebo-controlled period. Analyses were performed on prespecified subgroups based on baseline serum periostin levels. Following the discovery of a host-cell impurity in the study drug material, protocols were amended to convert from phase III to phase IIb. Subsequently, dosing of study medication was discontinued early as a precautionary measure. The data collected for analysis were from a placebo-controlled period of variable duration and pooled across both studies.

Results The median duration of treatment was approximately 24 weeks. Treatment with lebrikizumab reduced the rate of asthma exacerbations, which was more pronounced in the periostin-high patients (all doses: 60% reduction) than in the periostin-low patients (all doses: 5% reduction); no dose–response was evident. Lung function also improved following lebrikizumab treatment, with greatest increase in FEV1 in periostin-high patients (all doses: 9.1% placebo-adjusted improvement) compared with periostin-low patients (all doses: 2.6% placebo-adjusted improvement). Lebrikizumab was well tolerated and no clinically important safety signals were observed.

Conclusions These data are consistent with, and extend, previously published results demonstrating the efficacy of lebrikizumab in improving rate of asthma exacerbations and lung function in patients with moderate-to-severe asthma who remain uncontrolled despite current standard-of-care treatment.

Trial registration numbers The LUTE study was registered under NCT01545440 and the VERSE study under NCT01545453 at

  • Asthma
  • Cytokine Biology
  • Asthma Mechanisms

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

View Full Text

Statistics from

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    Andrew Bush Ian Pavord